Berkeley Capital Partners LLC Trims Stock Holdings in Bristol Myers Squibb Company $BMY

Berkeley Capital Partners LLC reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 30.7% during the 4th quarter, Holdings Channel reports. The fund owned 36,969 shares of the biopharmaceutical company’s stock after selling 16,397 shares during the period. Berkeley Capital Partners LLC’s holdings in Bristol Myers Squibb were worth $1,994,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in BMY. Man Group plc lifted its position in shares of Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of Bristol Myers Squibb by 530.6% in the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock valued at $245,946,000 after acquiring an additional 4,588,601 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Bristol Myers Squibb by 67.8% in the third quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock valued at $444,682,000 after acquiring an additional 3,982,439 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Bristol Myers Squibb by 31.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock valued at $669,012,000 after acquiring an additional 3,522,696 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Bristol Myers Squibb by 56.0% in the third quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock valued at $426,352,000 after acquiring an additional 3,396,041 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on BMY shares. Morgan Stanley reiterated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. UBS Group reiterated a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Piper Sandler reiterated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Royal Bank Of Canada started coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $56.40 on Thursday. The business’s 50-day moving average price is $58.83 and its 200 day moving average price is $55.25. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a market capitalization of $115.17 billion, a PE ratio of 15.84, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.3 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb signed a global collaboration and licensing deal with Hengrui Pharma covering 13 early-stage drug programs, potentially bringing in up to $15.2 billion in milestone payments and strengthening its R&D pipeline. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: The partnership gives Bristol Myers Squibb broader access to promising oncology, hematology, and immunology assets, which could support long-term growth and help offset future revenue losses from older drugs. China’s Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
• Neutral Sentiment: Recent coverage also highlighted that Bristol Myers Squibb beat first-quarter earnings and revenue estimates, which supports the stock’s fundamental story but is less immediate than the Hengrui announcement. Bristol-Myers Squibb Company (BMY) Myers Beats Quarterly Profit Estimates
• Negative Sentiment: Some reports note that BMY shares had been falling in recent sessions, reflecting ongoing investor caution around patent-cliff risks and valuation concerns before the deal news. Bristol-Myers Squibb shares fell for seventh consecutive session

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.